Effects of Cannabidiol on Appetite and Body Weight: A Systematic Review
ConclusionsThis systematic review suggests that cannabidiol has an anorexigenic effect, correlated with a decrease in body weight. However, most of the studies included in the present review raised some concerns in terms of risk of bias. We believe further research is needed in order to clarify potential mechanisms involved in the effect of cannabidiol on feeding/appetite. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 1, 2022 Category: Drugs & Pharmacology Source Type: research

Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database
ConclusionThe majority of AEs have been listed in the prescribing information or reported in previous studies, however we found significant disproportionality in some specific tumor- and liver-related AEs. Clinicians should pay more attention to the newly detected disproportionality that may be triggered by GLP-1RAs, especially in the vulnerable population after long-term use. Considering the limitations of the FAERS database, there is a need for additional pharmacoepidemiological approaches to validate the results of this study. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 30, 2022 Category: Drugs & Pharmacology Source Type: research

FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities
ConclusionsThe combination colchicine/prednisone compared with intravenous dexamethasone has shown a remarkable trend to increase disease survival over a 28-day period in elderly patients requiring oxygen therapy in geriatric centers, without safety issues.Clinical Trial RegistryClinical Trials Registration Number: NCT04492358. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 29, 2022 Category: Drugs & Pharmacology Source Type: research

Use of Azithromycin in Pregnancy: More Doubts than Certainties
AbstractMacrolides such as azithromycin are commonly prescribed antibiotics during pregnancy. The good oral bioavailability and transplacental transfer of azithromycin make this drug suitable for the treatment of sexually transmitted diseases, toxoplasmosis, and malaria. Moreover, azithromycin is useful both in the management of preterm pre-labor rupture of membranes and in the adjunctive prophylaxis for cesarean delivery. The aim of this comprehensive narrative review is to critically analyze and summarize the available literature on the main aspects of azithromycin use in pregnant women, with a special focus on adverse o...
Source: Clinical Drug Investigation - September 24, 2022 Category: Drugs & Pharmacology Source Type: research

Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China
ConclusionsThis budget impact analysis emphasized the positive effects of adopting a trastuzumab biosimilar in the healthcare system of China. However, cost savings still have a large potential to decrease by regulating pricing and by the procurement policy of biosimilars. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 17, 2022 Category: Drugs & Pharmacology Source Type: research

Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting Database
ConclusionThis pharmacovigilance study provides a characterization of cases indicative of COVID-19 reinfection with respect to reported use of immunosuppressant/immunomodulating agents. The observations generated from this cross-sectional observational analysis may prompt further research into the role of immunosuppression in COVID-19 reinfection, in an effort to better inform clinical practice and patient management. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 14, 2022 Category: Drugs & Pharmacology Source Type: research

Evaluation of the Effect of Uridine Diphosphate-Glucuronosyltransferases (UGT) Inhibition by Valproic Acid on Vixotrigine Pharmacokinetics in Healthy Volunteers
ConclusionsValproic acid, a uridine diphosphate-glucuronosyltransferase inhibitor, significantly increased vixotrigine systemic exposure.Clinical Trial RegistrationClinicalTrials.gov Identifier: NCT03385525. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 31, 2022 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression
ConclusionsRepeated subcutaneous esketamine administration had significant anti-suicidality effects in both major depressive disorder and bipolar groups, with a rapid onset of action and a good tolerability profile. Large randomized controlled trials are warranted to confirm these preliminary findings. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 31, 2022 Category: Drugs & Pharmacology Source Type: research

Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection
ConclusionsThe current study revealed that the median protective duration of ChAdOx1 and  BNT162b2 COVID-19 primary vaccination regimens administered in Saudi Arabia in 2021 was 134 days and that heterologous primary vaccination (ChAdOx1→BNT162b2) exhibited a significantly higher protective duration than other vaccination regimens. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 30, 2022 Category: Drugs & Pharmacology Source Type: research

Healthcare Utilization of Patients with Opioid Use Disorder in US Hospitals from 2016 to 2019: Focusing on Racial and Regional Variances
ConclusionSignificant differences in healthcare utilization exist between type of disorder, race, and region. Such findings illustrate that tailored treatment regimens are required to bridge the gaps in care and combat the opioid crisis. Minorities with opioid use disorder utilize healthcare the least, possibly because of affordability, and need culturally sensitive and financially feasible treatment options. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 24, 2022 Category: Drugs & Pharmacology Source Type: research

Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan
ConclusionThe incidence rates of local, systemic, and immediate hypersensitivity AEFIs of four COVID-19 vaccines occur frequently. High incidence rates of rare and serious AEFIs were reported in this study. Younger participants, females, those who had previously had COVID-19, and smokers were more likely to encounter AEFIs. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 23, 2022 Category: Drugs & Pharmacology Source Type: research

Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China
ConclusionsThe health economic evaluations revealed that for Chinese patients with reflux esophagitis, vonoprazan and the CYP2C19 genotype-guided strategy were not cost-effective regimens compared with lansoprazole. However, we found that in certain conditions like  a reduction in the price of vonoprazan and in patients with severe reflux esophagitis these could be cost-effective. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 22, 2022 Category: Drugs & Pharmacology Source Type: research

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care
ConclusionsInappropriate NOAC dosing is present in almost twenty percent of AF patients according to the SmPC and requires further education of health care professionals and frequent reassessment of NOAC dosing. However, a significant lower prevalence of underdosing was present when judged by the 2018 EHRA criteria, likely reflecting decision making in complex AF patients. Perceived frailty, weight, renal function and type of NOAC are the main determinants of deviated dosing. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 20, 2022 Category: Drugs & Pharmacology Source Type: research

Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study
ConclusionsBradycardia that occurs during or shortly after remdesivir treatment in COVID-19 patients may be associated with an increased rate of in-hospital mortality. However, COVID-19 and its cardiac complications cannot be excluded as potential contributors of bradycardia in the present study. Future studies are needed to further delineate the cardiac characteristics of COVID-19 and remdesivir. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 17, 2022 Category: Drugs & Pharmacology Source Type: research

Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor ( α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
ConclusionsRopanicant was found to be safe and well tolerated following single and multiple oral administrations in healthy subjects. Ropanicant showed nonlinear pharmacokinetics and accumulation following multiple dosing. Urinary excretion represents an insignificant elimination pathway for ropanicant. Ropanicant pharmacokinetics were sex dependent, and food and age had no effect on its  pharmacokinetics.Clinical Trial RegistrationNCT03155503 and NCT03551288. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 13, 2022 Category: Drugs & Pharmacology Source Type: research